Nurix Therapeutics, Inc. (NRIX)
26.14
+0.82
(+3.24%)
USD |
NASDAQ |
Sep 04, 16:00
26.13
-0.01
(-0.04%)
After-Hours: 20:00
Nurix Therapeutics SG&A Expense (TTM) : 57.01M for May 31, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| May 31, 2026 | 57.01M |
| February 28, 2026 | 55.70M |
| November 30, 2025 | 52.74M |
| August 31, 2025 | 49.81M |
| May 31, 2025 | 48.37M |
| February 28, 2025 | 45.80M |
| November 30, 2024 | 45.94M |
| August 31, 2024 | 46.01M |
| May 31, 2024 | 44.91M |
| February 29, 2024 | 44.88M |
| November 30, 2023 | 42.90M |
| August 31, 2023 | 41.49M |
| May 31, 2023 | 40.61M |
| February 28, 2023 | 38.59M |
| November 30, 2022 | 38.00M |
| Date | Value |
|---|---|
| August 31, 2022 | 37.45M |
| May 31, 2022 | 36.04M |
| February 28, 2022 | 33.90M |
| November 30, 2021 | 31.20M |
| August 31, 2021 | 28.64M |
| May 31, 2021 | 24.63M |
| February 28, 2021 | 20.39M |
| November 30, 2020 | 16.31M |
| August 31, 2020 | 12.66M |
| May 31, 2020 | 10.51M |
| February 29, 2020 | 9.106M |
| November 30, 2019 | 8.326M |
| August 31, 2019 | 5.724M |
| May 31, 2019 | 3.54M |
| February 28, 2019 | 1.67M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Monte Rosa Therapeutics, Inc. | 39.89M |
| Gilead Sciences, Inc. | 9.147B |
| TG Therapeutics, Inc. | 296.46M |
| Cue Biopharma, Inc. | 59.11M |
| Keros Therapeutics, Inc. | 40.62M |